Predictive factors of non-sentinel lymph node disease in breast cancer patients with positive sentinel lymph node

Cir Esp (Engl Ed). 2022 Feb;100(2):81-87. doi: 10.1016/j.cireng.2022.01.003. Epub 2022 Feb 3.

Abstract

Introduction: Management of positive sentinel lymph node biopsy (SLNB) in breast cancer remains a matter of debate. Our aim was to evaluate the incidence and identify predictive factors of non-sentinel lymph node metastases.

Methods: Retrospective review of all cN0 breast cancer patients treated between January 2013 and December 2017, with positive SLNB that were submitted to ALND.

Results: Of the 328 patients included, the majority of tumors were cT1 or cT2, with lymphovascular invasion in 58.4% of cases. The mean isolated nodes in SLNB was 2.7, with a mean of 1.6 positive nodes, 60.7% with extracapsular extension. Regarding ALND, a mean of 13.9 nodes were isolated, with a mean of 2.1 positive nodes. There was no residual disease in the ALND in 50.9% of patients, with 18.9% having ≥4 positive nodes. In the multivariate analysis, lymphovascular invasion, extracapsular extension in SLN, largest SLN metastases size (>10 mm) and ratio of positive SNL (>50%) were independent predictors of non-sentinel lymph node metastases. These four factors were used to build a non-pondered score to predict the probability of a positive ALND after a positive SLNB. The AUC of the model was 0.69 and 81% of patients with score = 0 and 65.6% with score = 1 had no additional disease in ALND.

Conclusion: The absence of non-sentinel lymph node metastases in the majority of patients with 1-2 positive SLN with low risk score questions the need of ALND in this population. The identified predictive factors may help select patients in which ALND can be omitted.

Keywords: Biopsia de ganglio centinela; Breast neoplasms; Cáncer de mama; Lymph node excision.

MeSH terms

  • Breast Neoplasms* / surgery
  • Female
  • Humans
  • Lymph Node Excision
  • Retrospective Studies
  • Sentinel Lymph Node Biopsy
  • Sentinel Lymph Node*